EP1267877A1 - VERWENDUNG VON PYRIDO 3,2-e]-PYRAZINONEN ALS INHIBITOREN DER PHOSPHODIESTERASE 5 ZUR THERAPIE VON EREKTILER DYSFUNKTION - Google Patents

VERWENDUNG VON PYRIDO 3,2-e]-PYRAZINONEN ALS INHIBITOREN DER PHOSPHODIESTERASE 5 ZUR THERAPIE VON EREKTILER DYSFUNKTION

Info

Publication number
EP1267877A1
EP1267877A1 EP01917067A EP01917067A EP1267877A1 EP 1267877 A1 EP1267877 A1 EP 1267877A1 EP 01917067 A EP01917067 A EP 01917067A EP 01917067 A EP01917067 A EP 01917067A EP 1267877 A1 EP1267877 A1 EP 1267877A1
Authority
EP
European Patent Office
Prior art keywords
methyl
methoxy
ethyl
pyπdo
ιmιdazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01917067A
Other languages
German (de)
English (en)
French (fr)
Inventor
Degenhard Marx
Norbert Höfgen
Ute Egerland
Stefan Szelenyi
Thomas Kronbach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elbion GmbH
Original Assignee
Arzneimittelwerk Dresden GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arzneimittelwerk Dresden GmbH filed Critical Arzneimittelwerk Dresden GmbH
Publication of EP1267877A1 publication Critical patent/EP1267877A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Definitions

  • This invention relates to the use of pyrido [3,2-e] -pyrazinones of the formula as active ingredients for the treatment of erectile dysfunction (impotence) and pharmaceutical preparations which contain these compounds.
  • Male impotence can be defined as his inability to have sexual intercourse due to lack of erection and / or lack of ejaculation.
  • Erectile dysfunction affects approximately 10% of the male population. Men between the ages of 40 and 70 are particularly affected with about 52%. Worldwide, several million men suffer from this disease (approx. 7.5 million in Germany alone), which in most cases is organic, less often psychological. Erectile dysfunction is a common problem among older men, especially when there are other chronic conditions such as high blood pressure, atherosclerosis and diabetes.
  • Silde ⁇ afil is an orally active phosphodiesterase 5 (PDE5) inhibitor, which does not directly cause an erection, but the effect of the sexual Stimulation of nitric oxide (NO) released in the penis increases NO, like its 'second messenger' cGMP, causes a vasodilation in the corpus cavemosum (swelling body) so that blood can flow in more, which causes the erection
  • Phosphodiesterases are an isoenzyme family to which 10 different isoenzymes have so far been assigned. PDE enzymes cleave by hydrolysis of cyclic guanos ⁇ n-3 ' , 5-monophosphate (cGMP) or cyclic adenos ⁇ n-3 ' , 5 ' -monophosphate ( cAMP), which occur as 'second messengers' in a large number of cells.
  • Phosphodiesterase 5 PDE 5
  • PDE 5 is cGMP-specific and dominates in the tissue of the human corpus cavernosum
  • the inhibition of PDE 5 in the human cavernous body leads to an increase in the intracellular cGMP level induced by NO. This is associated with relaxation of the smooth muscles of the cavernous body and, as a result, an erection
  • Inhibitors of PDE 5 are therefore suitable as therapeutic agents for the indication of erectile dysfunction
  • European patent 0 400 583 relates to imidazoquinoxane of the general formula
  • A represents a nitrogen atom or CH
  • B and D represent a nitrogen atom or CH or a substituted carbon atom for positions 7 or 8
  • the radicals R, R ⁇ , R2 represent hydrogen or various organic substituents
  • Patent application WO 93/20 077 relates to imidazoquinoxahnones of the general formula
  • R 1 can be NO2 or CF3 and X for various nitrogen-containing ones
  • the invention relates to Py ⁇ do [3,2-e] -pyraz ⁇ none of formula 1
  • R, R 2 , R 4 may be the same or different and represent -C ⁇ - alkyl groups, which may be straight-chain or branched-chain, and R 3 for -CH 2 -A stands for A can
  • the invention also relates to the physiologically acceptable salts of the compounds of the formula 1, which can be obtained by neutralizing the bases with inorganic or organic acids or by neutralizing the acids with inorganic or organic bases or by quaternizing tertiary amines to form quaternary ammonium salts
  • Formulas are known per se from patent DE 195 10 965, to which reference has already been made in the prior art, where pyrido [3,2-e] pyrazionones were identified as dual inhibitors of PDE 4 and PDE 5, which also means that described application as anti-asthmatics or anti-allergies
  • Those compounds of the formula ⁇ according to the invention in which A is a cyclohexyl group and R 1 , R 2 and R 4 have the meaning described are new
  • the compounds of the formula according to the invention are distinguished by the fact that their inhibitory action on PDE 5 is particularly pronounced. It is the essence of this invention that the compounds according to the formula ⁇ according to the invention are particularly suitable for use as therapeutic agents for the treatment of erectile dysfunction by this active principle are
  • a particular advantage of the compounds according to the invention is that they affect the cGMP level in human tissue with a high selectivity, but not the cAMP level. This has been shown for both human tissue of the heart and of the penis. With this selectivity, the risk of heart Circulatory side effects are minimized With regard to cGMP selectivity, the compounds according to the invention are superior to the standard therapeutic agent sildenafil
  • the compounds of the formula ⁇ according to the invention can be administered systemically, for example intravenously, intramuscularly, subcutaneously, orally, buccally or sub ngually.
  • Topical application for example by inhalation or intranasally, is also possible.
  • Oral application of 5-200 mg of the compound before sexual intercourse is a preferred therapy regimen
  • Medicaments which contain one or more of the compounds of the formula according to the invention in addition to conventional physiologically acceptable carriers and / or diluents or auxiliaries, and also processes for the preparation of these medicaments are also part of this invention
  • the compounds of formula 1 according to the invention and the medicaments which contain the compounds of formula 1 according to the invention can be used both individually and in combination with one another
  • the compounds according to the invention can be used as veterinary therapeutic agents for the prophylaxis and therapy of erectile dysfunction in male mammals.
  • the dosage, the application scheme and the galenical formulation of the compound are carried out taking into account species differences and the requirements of veterinary practice
  • the compounds according to the invention are strong inhibitors of phosphodiesterase 5. Their therapeutic potential is demonstrated in vitro, for example, by increasing the effect of NO on the intracellular cGMP levels in fibroblasts in the rat, the selectivity of influencing the cAMP and cGMP levels in human tissues and the Relaxation of human corpus cavernosum demonstrated
  • the PDE 5 actinate is determined in enzyme preparations from human platelets. Human blood was anticoagulated with citrate. By centrifugation at 700 xg for 20 minutes at room temperature, the platelet-rich plasma in the supernatant is separated from the erythrocytes and leukocytes.
  • the platelets are lysed by ultrasound and in the PDE 5-assay used
  • the phosphodiesterase activity is determined with some modifications according to the method described by Thompson et al (Thompson, WJ, Appleman, MM, Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme Adv Cycl Nucl Res 1979, 10, 69-92)
  • the reaction mixtures contain 50 mM Tris-HCl (pH 7.4), 5 mM MgCl2, the inhibitors in variable concentrations, the enzyme preparation and the further components necessary for the detection of the individual isoenzyme PDE 5 (see below) the addition of the substrate 0.5 ⁇ M [ 3 H] -cGMP (approx.
  • the samples are stopped on ice, 400 ⁇ l each of a mixture of Dowex-water-ethanol (1 +1 +1) are added , well mixed and incubated again on ice for 15 minutes.
  • the reaction vessels are centrifuged for 20 minutes at 3000 xg. 200 ⁇ l aliquots of the supernatant are transferred directly into scintillation vials. After the addition of 3 ml scintillator, the samples are measured in a beta counter 100 ⁇ M IBMX determined in the determination of PDE 5 and subtracted from the test values
  • Rat fetal lung fibroblast cells are a suitable medium for examining the influence of NO on intracellular cGMP levels (Ishn et al 1991).
  • the basic mechanism is based on the smooth vascular muscles transferable in the corpus cavernosum
  • the compounds according to the invention intensify the concentration-dependent increase in the intracellular cGMP levels induced by the NO donor S-nitroso-N-acetyl-D, l_-pen ⁇ c ⁇ llam ⁇ n
  • compound 13 induces a significant increase in cGMP level at a concentration of 0.10 ⁇ mol / l.
  • the effectiveness of compound 13 is 1000 times stronger than that which is achieved by using the non-specific PDE inhibitor 3-isobutyl-1 - methylxanth ⁇ n (IBMX) reached
  • the compounds according to the invention are superior to the standard therapeutic agent sildenafil.
  • Sildenafil increases the cGMP level in human atrium tissue by 147%, and the cAMP level at the same time by 240%.
  • the cGMP is increased by sildenafil.
  • the compounds according to the invention have a relaxing effect on the corpus cavernosum strips pre-contracted with Noradrenahn. For example, an EC50 value of 0 15 ⁇ mol / l was determined for compound 13

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP01917067A 2000-03-14 2001-03-06 VERWENDUNG VON PYRIDO 3,2-e]-PYRAZINONEN ALS INHIBITOREN DER PHOSPHODIESTERASE 5 ZUR THERAPIE VON EREKTILER DYSFUNKTION Withdrawn EP1267877A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10012373A DE10012373A1 (de) 2000-03-14 2000-03-14 Verwendung von Pyrido[3,2-e]-pyrazinonen als Inhibitoren der Phosphodiesterase 5 zur Therapie von erektiler Dysfunktion
DE10012373 2000-03-14
PCT/EP2001/002485 WO2001068097A1 (de) 2000-03-14 2001-03-06 VERWENDUNG VON PYRIDO[3,2-e]-PYRAZINONEN ALS INHIBITOREN DER PHOSPHODIESTERASE 5 ZUR THERAPIE VON EREKTILER DYSFUNKTION

Publications (1)

Publication Number Publication Date
EP1267877A1 true EP1267877A1 (de) 2003-01-02

Family

ID=7634668

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01917067A Withdrawn EP1267877A1 (de) 2000-03-14 2001-03-06 VERWENDUNG VON PYRIDO 3,2-e]-PYRAZINONEN ALS INHIBITOREN DER PHOSPHODIESTERASE 5 ZUR THERAPIE VON EREKTILER DYSFUNKTION

Country Status (14)

Country Link
EP (1) EP1267877A1 (ja)
JP (1) JP2003528056A (ja)
AR (1) AR028250A1 (ja)
AU (1) AU2001244192A1 (ja)
BG (1) BG107077A (ja)
BR (1) BR0109163A (ja)
CZ (1) CZ20023078A3 (ja)
DE (1) DE10012373A1 (ja)
HU (1) HUP0300551A2 (ja)
IL (1) IL151646A0 (ja)
NO (1) NO20024364L (ja)
RU (1) RU2002127413A (ja)
SK (1) SK13232002A3 (ja)
WO (1) WO2001068097A1 (ja)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
ES2365966T3 (es) 2007-09-14 2011-10-14 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-disustituidas.
PT2203439E (pt) 2007-09-14 2011-02-11 Ortho Mcneil Janssen Pharm 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridinil-2'- onas 1',3'-dissubstituídas
KR20100110804A (ko) 2007-11-30 2010-10-13 와이어쓰 엘엘씨 포스포디에스테라제 10의 저해물질로서의 아릴 및 헤테로아릴 융합된 이미다조[1,5-ａ]피라진
CA2735764C (en) 2008-09-02 2016-06-14 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
MX2011005242A (es) 2008-11-28 2011-09-06 Ortho Mcneil Janssen Pharm Derivados de indol y benzoxazina como moduladores de los receptores de glutamato metabotropicos.
MX2011011964A (es) 2009-05-12 2012-02-23 Janssen Pharmaceuticals Inc Derivados de 1,2,3-triazolo[4,3-a]piridina y su uso para el tratamiento o prevencion de trastornos neurologicos y psiquiatricos.
AR076859A1 (es) 2009-05-12 2011-07-13 Ortho Mcneil Janssen Pharm Derivados de 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2 , composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos.
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN103298809B (zh) 2010-11-08 2016-08-31 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
PL2649069T3 (pl) 2010-11-08 2016-01-29 Janssen Pharmaceuticals Inc Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MX357320B (es) 2012-06-18 2018-07-04 Dart Neuroscience Cayman Ltd Compuestos de la azolopirimidina-5-(6h)-ona de piridina sustituida.
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
AU2015208233B2 (en) 2014-01-21 2019-08-29 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
PT3096790T (pt) 2014-01-21 2019-10-15 Janssen Pharmaceutica Nv Combinações compreendendo moduladores alostéricos positivos ou agonistas ortostéricos do recetor glutamatérgico metabotrópico do subtipo 2 e seu uso
JP6420400B2 (ja) * 2017-04-12 2018-11-07 ダート・ニューロサイエンス・（ケイマン）・リミテッド 置換ピリジンアゾロピリミジン−５−（６ｈ）−オン化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055465A (en) * 1989-05-31 1991-10-08 Berlex Laboratories, Inc. Imidazoquinoxalinones, their aza analogs and process for their preparation
WO1993020077A1 (en) * 1992-04-03 1993-10-14 Yamanouchi Pharmaceutical Co., Ltd. Fused quinoxalinone derivative and pharmaceutical composition containing the same
DE4228095A1 (de) * 1992-08-24 1994-03-03 Asta Medica Ag Neue 4,5-Dihydro-4-oxo-pyrrolo[1,2-a]chinoxaline und entsprechende Aza-analoga und Verfahren zu deren Herstellung
DE4338948A1 (de) * 1993-11-15 1995-05-18 Carlen Judith Verwendung von PDE-Inhibitoren bei der Behandlung erektiler Dysfunktionen
DE19510965A1 (de) * 1995-03-24 1996-09-26 Asta Medica Ag Neue Pyrido/3,2-e/pyrazinone mit antiasthmatischer Wirksamkeit und Verfahren zu deren Herstellung
DE19728301A1 (de) * 1997-07-03 1999-01-07 Dresden Arzneimittel Verwendung von Inhibitoren der Phosphodiesterase 4 für die Behandlung der allergischen Rhinitis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0168097A1 *

Also Published As

Publication number Publication date
JP2003528056A (ja) 2003-09-24
BG107077A (bg) 2003-05-30
WO2001068097A1 (de) 2001-09-20
NO20024364L (no) 2002-09-27
CZ20023078A3 (cs) 2003-03-12
NO20024364D0 (no) 2002-09-12
DE10012373A1 (de) 2001-09-20
IL151646A0 (en) 2003-04-10
HUP0300551A2 (hu) 2003-07-28
AR028250A1 (es) 2003-04-30
AU2001244192A1 (en) 2001-09-24
BR0109163A (pt) 2002-11-26
SK13232002A3 (sk) 2003-05-02
RU2002127413A (ru) 2004-02-27

Similar Documents

Publication Publication Date Title
EP1267877A1 (de) VERWENDUNG VON PYRIDO 3,2-e]-PYRAZINONEN ALS INHIBITOREN DER PHOSPHODIESTERASE 5 ZUR THERAPIE VON EREKTILER DYSFUNKTION
US6300335B1 (en) 4-aminoquinazoline derivative cGMP-PDE inhibitors for the treatment of erectile dysfunction
DE69833671T2 (de) KOMBINATION AUS EINEM ALPHA-1-ADRENOREZEPTOR ANTAGONISTEN UND EINEM CGM PDEv HEMMER ZUR BEHANDLUNG VON IMPOTENZ
WO2000043392A2 (de) Verwendung von imidazo[1,5-a]-pyrido[3,2-e]-pyrazinonen als arzneimittel
DE20007861U1 (de) Hergestellte Artikel mit Phosphodiesterase-Inhibitor
DE1817843A1 (de) Arzneimittel zur Relaxion glatter Muskeln
EP1148888A2 (de) Behandlung von erektilen dysfunktionen mit c-typ natriuretischem polypeptid (cnp) als monotherapie oder in kombination mit phosphodiesterasehemmern
US6465465B1 (en) Process for the treatment of erectile dysfunction and product therefor
Eardley The role of phosphodiesterase inhibitors in impotence
CA2080825A1 (en) Minoxidil for treating erectile impotence
DE60213798T2 (de) Carbolinderivate als pdev inhibitoren
US20020013280A1 (en) Pharmaceutical composition for preventing and treating sexual dysfunction and vasculargenic disease comprising icariin
DE69935733T2 (de) Verwendung einer kombination aus einem purin und einem no-donor zur behandlung und prophylaxe sexueller funktionsstörungen
DE19902082A1 (de) Verwendung von Imidazo[1,5-a]-pyrido[3,2-e]-pyrazinonen als Inhibitoren der Phosphodiesterase 5 zur Therapie von erectiler Dysfunktion und Verfahren zu deren Herstellung
EP0995441B1 (de) Medikamentenkombination zur Therapie der erektilen Dysfunktion
DE19961302A1 (de) Verwendung von Imidazo(1,5-a)-pyrido(3,2-e)-pyrazinonen als duale Inhibitoren der Phosphodiesterase 5 und der Phosphodiesterase 3 zur Therapie der Herzinsuffizienz, von pulmonaler Hypertonie und Gefäßerkrankungen, die mit einer Minderdurchblutung einhergehen
WO2000007541A2 (de) Verwendung von xanthinderivaten zur behandlung von erektionsstörungen
DE19834604A1 (de) Verwendung von Xanthinderivaten zur Behandlung von Erektionsstörungen
CH643458A5 (en) Pharmaceutical composition and a process for its production
DE19841051A1 (de) Verwendung von Xanthinderivaten zur Behandlung von Erektionsstörungen
DE19919828A1 (de) Verwendung von Xanthinderivaten zur Behandlung von Erektionsstörungen
TWI235062B (en) A combination of the medicine for the prevention and treatment of sexual disorder and vasoconstrictive diseases
MXPA01007380A (en) Use of imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones as medicaments
Blum et al. Intensification of amphetamine-induced excitation by methysergide, a serotonergic receptor blocker
KR20020095469A (ko) 발기부전을 치료하기 위한, 피리도[3,2-ｅ]-피라지논의포스포디에스테라제 5의 억제제로서의 용도

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020903

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT PAYMENT 20020903;LV PAYMENT 20020903;MK PAYMENT 20020903;RO PAYMENT 20020903;SI PAYMENT 20020903

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ELBION AG

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MARX, DEGENHARD

Inventor name: SZELENYI, STEFAN

Inventor name: KRONBACH, THOMAS

Inventor name: HOEFGEN, NORBERT

Inventor name: EGERLAND, UTE

17Q First examination report despatched

Effective date: 20030813

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20031001

RTI1 Title (correction)

Free format text: USE OF PYRIDO 3,2-E -PYRAZINONES AS INHIBITORS OF PHOSPHODIESTERASE 5 FOR TREATING ERECTILE DYSFUNCTION